Search results for "AGONIST"

showing 10 items of 2285 documents

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

2017

Background and Purpose Mirabegron has been classified as a β3-adrenoceptor agonist approved for overactive bladder syndrome. We investigated possible cardiac effects of mirabegron in the absence or presence of β-adrenoceptor subtype antagonists. In view of its phenylethanolamine structure, we investigated whether mirabegron has indirect sympathomimetic activity by using neuronal uptake blockers. Experimental Approach Right atrial trabeculae, from non-failing hearts, were paced and contractile force measured at 37°C. Single concentrations of mirabegron were added in the absence or presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), β3 (L-748,337), β1 (CGP 20712A),…

0301 basic medicinePharmacologyAgonistmedicine.medical_specialtyIBMXContraction (grammar)PhenoxybenzamineChemistrymedicine.drug_classAdrenergicPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biologyEndocrinologyInternal medicineDesipraminemedicinePhosphodiesterase inhibitorMirabegronmedicine.drugBritish Journal of Pharmacology
researchProduct

How β3 -adrenoceptor-selective is mirabegron?

2016

0301 basic medicinePharmacologybusiness.industryAdrenergic beta-3 Receptor AgonistsPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicineβ3 adrenoceptorMirabegronbusiness030217 neurology & neurosurgerymedicine.drugBritish Journal of Pharmacology
researchProduct

2021

Angiotensin II (Ang II) has been implicated in the pathophysiology of various age-dependent ocular diseases. The purpose of this study was to test the hypothesis that Ang II induces endothelial dysfunction in mouse ophthalmic arteries and to identify the underlying mechanisms. Ophthalmic arteries were exposed to Ang II in vivo and in vitro to determine vascular function by video microscopy. Moreover, the formation of reactive oxygen species (ROS) was quantified and the expression of prooxidant redox genes and proteins was determined. The endothelium-dependent artery responses were blunted after both in vivo and in vitro exposure to Ang II. The Ang II type 1 receptor (AT1R) blocker, candesar…

0301 basic medicinePhysiologyClinical BiochemistryVideo microscopyVasodilation030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicinemedicineEndothelial dysfunctionMolecular BiologyAngiotensin II receptor type 1biologyChemistryCell Biologymedicine.diseaseAngiotensin IINitric oxide synthaseCandesartan030104 developmental biologycardiovascular systembiology.proteinhormones hormone substitutes and hormone antagonistsOxidative stressmedicine.drugAntioxidants
researchProduct

The Role of Sirtuin1 in Regulating Endothelial Function, Arterial Remodeling and Vascular Aging

2019

Sirtuin1 (SIRT1), which belongs to a highly conserved family of protein deacetylase, is one of the best-studied sirtuins. SIRT1 is involved in a variety of biological processes, including energy metabolism, cell proliferation and survival, chromatin dynamics, and DNA repair. In the vasculature, SIRT1 is ubiquitously expressed in endothelial cells, smooth muscle cells, and perivascular adipose tissues (PVAT). Endothelial SIRT1 plays a unique role in vasoprotection by regulating a large variety of proteins, including endothelial nitric oxide synthase (eNOS). In endothelial cells, SIRT1 and eNOS regulate each other synergistically through positive feedback mechanisms for the maintenance of end…

0301 basic medicinePhysiologyDNA repairvascular remodelingAdipose tissueReview030204 cardiovascular system & hematologylcsh:Physiology03 medical and health sciencesSIRT10302 clinical medicineEnosPhysiology (medical)lcsh:QP1-981biologyCell growthbiology.organism_classificationChromatinCell biologyenzymes and coenzymes (carbohydrates)030104 developmental biologyvascular agingPVATeNOSProtein deacetylaseVascular aginghormones hormone substitutes and hormone antagonistsFunction (biology)Frontiers in Physiology
researchProduct

How Can Interleukin-1 Receptor Antagonist Modulate Distinct Cell Death Pathways?

2018

Multiple mechanisms of cell death exist (apoptosis, necroptosis, pyroptosis) and the subtle balance of several distinct proteins and inhibitors tightly regulates the cell fate toward one or the other pathway. Here, by combining coimmunoprecipitation, enzyme assays, and molecular simulations, we ascribe a new role, within this entangled regulatory network, to the interleukin-1 receptor antagonist (IL-1Ra). Our study enlightens that IL-1Ra, which usually inhibits the inflammatory effects of IL-1α/β by binding to IL-1 receptor, under advanced pathological states prevents apoptosis and/or necroptosis by noncompetitively inhibiting the activity of caspase-8 and -9. Consensus docking, followed by…

0301 basic medicineProgrammed cell deathProtein ConformationGeneral Chemical EngineeringNecroptosis-Library and Information SciencesMolecular Dynamics SimulationInhibitor of apoptosis01 natural sciencesArticle03 medical and health sciences0103 physical sciencesReceptorsmedicineCaspaseCaspase 8010304 chemical physicsbiologyCell DeathChemistryNeurodegenerationPyroptosisComputational BiologyReceptors Interleukin-1General Chemistrymedicine.diseaseCaspase 9Computer Science ApplicationsCell biologyXIAPEnzyme ActivationInterleukin 1 Receptor Antagonist Protein030104 developmental biologyApoptosisbiology.proteinThermodynamicsInterleukin-1
researchProduct

E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death

2018

International audience; E2F1 is the main pro-apoptotic effector of the pRB-regulated tumor suppressor pathway by promoting the transcription of various pro-apoptotic proteins. We report here that E2F1 partly localizes to mitochondria, where it favors mitochondrial outer membrane permeabilization. E2F1 interacts with BCL-xL independently from its BH3 binding interface and induces a stabilization of BCL-xL at mitochondrial membranes. This prevents efficient control of BCL-xL over its binding partners, in particular over BAK resulting in the induction of cell death. We thus identify a new, non-BH3-binding regulator of BCL-xL localization dynamics that influences its anti-apoptotic activity.

0301 basic medicineProgrammed cell deathTranscription Geneticbcl-X ProteinRegulatorBcl-xL[SDV.CAN]Life Sciences [q-bio]/CancerBCL-xL mobilityMitochondrionBiochemistrylaw.invention[ SDV.CAN ] Life Sciences [q-bio]/CancerE2F1 Subject Category Autophagy & Cell Death03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerlawBCL-2 familyCell Line TumorGeneticsJournal ArticleHumansE2F1Molecular BiologyCell DeathbiologyManchester Cancer Research CentreEffectorChemistryResearchInstitutes_Networks_Beacons/mcrcScientific ReportsapoptosisSubcellular localizationMitochondriaCell biologyProtein Transportbcl-2 Homologous Antagonist-Killer Protein030104 developmental biologyGene Expression RegulationProto-Oncogene Proteins c-bcl-2biology.proteinSuppressorbiological phenomena cell phenomena and immunityExtracellular SpaceE2F1 Transcription FactorProtein Binding
researchProduct

Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β 2 -adrenoceptor agonist (MA…

2017

LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases. This study investigated the pharmacological profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol. LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays). It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compounds (pEC50 in spontaneous tone isolated trachea: 9.6). The relaxant potency of LAS190792 in electrically stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol sl…

0301 basic medicinePulmonary and Respiratory MedicineAgonistmedicine.drug_classBiochemistry (medical)OlodaterolAntagonistMuscarinic acetylcholine receptor M3Muscarinic antagonistPropranololPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicine030228 respiratory systemchemistryCompetitive antagonistMuscarinic acetylcholine receptormedicinePharmacology (medical)medicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

mcr-1- like detection in commensal Escherichia coli and Salmonella spp. from food-producing animals at slaughter in Europe

2017

International audience; We evaluate here the presence of the mcr-1-like and mcr-2 genes in Escherichia coli and Salmonella spp. isolated from healthy food-producing animals at slaughter between 2002 and 2014 in Europe. Isolates were retrieved from cattle, pig and chicken from 11 European countries of production. The susceptibility to colistin and antibiotics used in human medicine was determined by agar dilution. Colistin-resistant isolates were PCR-screened for mcr genes. mcr-positive isolates were typed by Pulsed-Field Gel Electrophoresis (PFGE) and Multi-Locus Sequence Typing. Among the 10,206 E. coli and 1774 Salmonella spp. isolated from cattle, pigs and chickens, 148 E. coli and 92 Sa…

0301 basic medicineSalmonellaVeterinary medicineFood-producing animalsmedicine.drug_classSwine030106 microbiologyAntibioticsBiology[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.disease_causeMicrobiologyAgar dilution03 medical and health sciencesBacterial Proteins[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologySalmonellaDrug Resistance BacterialmedicinePulsed-field gel electrophoresisEscherichia coliAnimalsTypingEscherichia coliEscherichia coli Infections2. Zero hungerSalmonella Infections AnimalGeneral VeterinaryColistinEscherichia coli ProteinsGeneral Medicine[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthAnti-Bacterial AgentsBacterial Typing TechniquesElectrophoresis Gel Pulsed-FieldEuropeSalmonella spp.ColistinMCR-1CattleChickensMCR-1Abattoirshormones hormone substitutes and hormone antagonistsmedicine.drugMultilocus Sequence Typing
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications

2021

Preclinical studies provided some important insights into the action of glucagon-like peptide 1 (GLP-1) in taste perception. This review examines the literature to uncover some molecular mechanisms and connections between GLP-1 and the gustatory coding. Local GLP-1 production in the taste bud cells, the expression of GLP-1 receptor on the adjacent nerves, a functional continuum in the perception of sweet chemicals from the gut to the tongue and an identification of GLP-1 induced signaling pathways in peripheral and central gustatory coding all strongly suggest that GLP-1 is involved in the taste perception, especially sweet. However, the impact of GLP-1 based therapies on gustatory coding i…

0301 basic medicineTasteendocrine systemobesitymedia_common.quotation_subject030209 endocrinology & metabolismReviewBiologyCatalysisGlucagon-Like Peptide-1 Receptorlcsh:ChemistryInorganic Chemistrytaste03 medical and health sciences0302 clinical medicineTreatment targetsTonguetongueGlucagon-Like Peptide 1PerceptionmedicineAnimalsHumansGLP-1 Sweet Taste Tongue Animals Glucagon-Like Peptide-1 Receptor Humans Obesity Signal Transduction Taste Taste Buds Taste PerceptionPhysical and Theoretical ChemistryReceptorTaste Bud Cellslcsh:QH301-705.5Molecular BiologySpectroscopymedia_commonOrganic Chemistrydigestive oral and skin physiologyTaste PerceptionGeneral MedicineTaste BudsGlucagon-like peptide-1Computer Science Applications030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Signal transductionGLP-1Neurosciencesweethormones hormone substitutes and hormone antagonistsSignal TransductionInternational Journal of Molecular Sciences
researchProduct